Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Edaravone→

Edaravone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
89-25-8
PubChem CID
4021
Molecular formula
C10H10N2O
Molecular weight
174.20 g/mol
Drug class
Free-radical scavengerantioxidant neuroprotective small molecule
Mechanism of action
The mechanism by which edaravone produces clinical benefit in amyotrophic lateral sclerosis (ALS) is not fully understood. It scavenges free radicals and may reduce oxidative stress and lipid peroxidation; these effects should not be equated with a proven disease-modifying molecular pathway.
Indications / reported uses
  • Treatment of amyotrophic lateral sclerosis (ALS) in adults under the US product indication; the clinical benefit is described as slowing decline in physical function in the studied population

Sources: US DailyMed — RADICAVA / RADICAVA ORS (edaravone) · US FDA prescribing information · FDA product information

Identification source: PubChem record (CID 4021). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Free-radical scavenger; antioxidant neuroprotective small molecule

Mechanism of action

The mechanism by which edaravone produces clinical benefit in amyotrophic lateral sclerosis (ALS) is not fully understood. It scavenges free radicals and may reduce oxidative stress and lipid peroxidation; these effects should not be equated with a proven disease-modifying molecular pathway.

General use cases

  • Treatment of amyotrophic lateral sclerosis (ALS) in adults under the US product indication; the clinical benefit is described as slowing decline in physical function in the studied population

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Edaravone Environmental Risk Assessment (ERA) (the Edaravone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.